Abstract:Precision medicine relies on the idea that, for a particular targeted agent, only a subpopulation of patients is sensitive to it and thus may benefit from it therapeutically. In practice, it is often assumed based on preclinical data that a treatment-sensitive subpopulation is known, and moreover that the agent is substantively efficacious in that subpopulation. Due to important differences between preclinical settings and human biology, however, data from patients treated with a new targeted agent often show that one or both of these assumptions are false. This paper provides a Bayesian randomized group sequential enrichment design that compares an experimental treatment to a control based on survival time and uses early response as an ancillary outcome to assist with adaptive variable selection and enrichment. Initially, the design enrolls patients under broad eligibility criteria. At each interim decision, submodels for regression of response and survival time on a baseline covariate vector and treatment are fit; variable selection is used to identify a covariate subvector that characterizes treatment-sensitive patients and determines a personalized benefit index, and comparative superiority and futility decisions are made. Enrollment of each cohort is restricted to the most recent adaptively identified treatment-sensitive patients. Group sequential decision cutoffs are calibrated to control overall type I error and account for the adaptive enrollment restriction. The design provides a basis for precision medicine by identifying a treatment-sensitive subpopulation, if it exists, and determining whether the experimental treatment is superior to the control in that subpopulation. A simulation study shows that the proposed design reliably identifies a sensitive subpopulation, yields much higher generalized power compared to several existing enrichment designs and a conventional all-comers group sequential design, and is robust.

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

MIDAS: a Practical Bayesian Design for Platform Trials with Molecularly Targeted Agents

ComPAS: A Bayesian Drug Combination Platform Trial Design with Adaptive Shrinkage

A Bayesian latent-subgroup platform design for dose optimization

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

Bayesian Optimal Phase II Designs with Dual‐criterion Decision Making

Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

Shotgun: A Bayesian Seamless Phase I-II Design to Accelerate the Development of Targeted Therapies and Immunotherapy.

A Bayesian Decision-Theoretic Design for Simultaneous Biomarker-Based Subgroup Selection and Efficacy Evaluation

A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

A Bayesian Phase I/II Trial Design for Immunotherapy

Bayesian Optimal Phase II Design for Randomized Clinical Trials